Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.60 |
| ▸ | CTSS | P25774 | 4/20 | 0.60 |
| ▸ | CTSK | P43235 | 6/20 | 0.59 |
| ▸ | CTSB | P07858 | 5/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | CASP9 | P55211 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5967917 | 1.00 | CTSL (0.60) | CTSLCTSSCTSKCTSBCASP3 | |
| SCHEMBL12588646 | 0.97 | CASP3 (0.59) | CTSLCTSSCTSKCTSBCASP3 | |
| SCHEMBL13888699 | 0.97 | CASP3 (0.59) | CTSLCTSSCTSKCTSBCASP3 | |
| SCHEMBL12588645 | 0.97 | CASP3 (0.59) | CTSLCTSSCTSKCTSBCASP3 | |
| SCHEMBL5967873 | 0.91 | ECE1 (0.55) | CTSLCTSSCTSKCTSBCASP3 | |
| SCHEMBL25693730 | 0.90 | CTSS (0.73) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL19557810 | 0.89 | CASP3 (0.61) | CTSLCTSSCTSKCTSBCASP3 | |
| SCHEMBL10453618 | 0.89 | CASP3 (0.61) | CTSLCTSSCTSKCTSBCASP3 | |
| SCHEMBL8658774 | 0.88 | MEN1 (0.74) | CTSLCTSSCTSKCTSBCASP3 | |
| SCHEMBL13888698 | 0.88 | MEN1 (0.74) | CTSLCTSSCTSKCTSBCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | BLADE THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | BLADE THERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-7517566-B2 | Liquid crystal composition containing at least two gelling agents showing a liquid crystal phase at room temperature, one of which is self-organizing and has an intermolecular binding group-containing unit and a saturated aliphatic hydrocarbon group; improved in whiteness and brightness | KONICA MINOLTA HOLDINGS, INC. (JP) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | CAPN1, CAPN9, CAPN2 | CTSL 1363/4885CTSS 905/4885CTSK 566/4885 |
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | CAPN1, CAPN9, CAPN2 | CTSL 1363/4885CTSS 905/4885CTSK 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.